Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double-masked, Parallel-group Clinical Trial Evaluating the Bioequivalence and Safety of a Single Subcutaneous Dose of IBI3027 Monoclonal Antibody Injection Versus DUPIXENT® (Dupilumab) in Healthy Adult Chinese Male Volunteers.

NCT07502534 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.

NCT NCT07502534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07502534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double-masked, Parallel-group Clinical Trial Evaluating the Bioequivalence and Safety of a Single Subcutaneous Dose of IBI3027 Monoclonal Antibody Injection Versus DUPIXENT® (Dupilumab) in Healthy Adult Chinese Male Volunteers.
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 24, 2026
Completion date
July 7, 2026
Enrollment
180 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers